The Centers for Medicare & Medicaid Services reported it will offer coverage for transcatheter aortic valve replacement (TAVR) only under a coverage with evidence development framework, but despite the misgivings many in the device industry have about coverage with evidence development (CED), the only device maker with an approved device finds the decision flexible and promising with regard to future indications.